Related Experiment Video
Updated: Jan 23, 2026

A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Patient-derived xenograft models to optimize kidney cancer therapies
Avi Patel1, Sarah Cohen1, Ravan Moret1
1UQ-Ochsner Clinical School, Institute for Translational Research, Ochsner Clinic Foundation, New Orleans, LA, USA.
Abstract:
Renal cell carcinoma (RCC) is the most common solid neoplasm of the adult kidney and has a high potential for developing metastatic spread. Approximately 25-30% of RCC patients have metastatic disease at presentation, and 30-40% of patients develop metastases after the initial diagnosis. Advanced renal cancer is a deadly and difficult-to-treat cancer. The 5-year survival rate of patients with metastatic disease is less than 10%, partly because RCC metastases become resistant to current therapies. Pre-clinical models may help to identify the optimum therapeutic options for individual patients. Here we reviewed various mouse xenograft methods for RCC treatment screening especially patient-derived orthotopic xenograft models. Advantages and disadvantaged of some of the models are also discussed.
Insights
This review explores mouse xenograft models for screening renal cell carcinoma (RCC) treatments. Patient-derived orthotopic xenografts show promise for identifying effective therapies against this deadly kidney cancer.
Area of Science:
- Oncology
- Translational Medicine
Background:
- Renal cell carcinoma (RCC) is a common adult kidney cancer with high metastatic potential.
- Metastatic RCC presents a significant challenge, with poor survival rates due to treatment resistance.
Purpose of the Study:
- To review preclinical mouse xenograft models for screening renal cell carcinoma (RCC) treatments.
- To discuss the advantages and disadvantages of various models, particularly patient-derived orthotopic xenografts (PDX).
Main Methods:
- Review of existing literature on mouse xenograft models for RCC.
- Focus on patient-derived orthotopic xenograft (PDX) models for treatment screening.
Main Results:
- Various mouse xenograft models exist for RCC treatment screening.
- PDX models offer a promising approach for evaluating therapeutic options.
Conclusions:
- Preclinical models, especially PDX, are crucial for identifying optimal therapies for individual RCC patients.
- Further research into these models can improve treatment strategies for advanced renal cancer.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:42Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
Published on: July 19, 2019
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Kidney Structure
Gene Therapy
Optimal Foraging